Explore
Validate
Learn
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA026588 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA026588, RRID:AB_1847812
- Product name
- Anti-DNMT3A
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human DNMT3A, Gene description: DNA (cytosine-5-)-methyltransferase 3 alpha, Validated applications: IHC, ICC, Uniprot ID: Q9Y6K1, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapy
DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis
Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.
Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells
Bai W, Xu J, Gu W, Wang D, Cui Y, Rong W, Du X, Li X, Xia C, Gan Q, He G, Guo H, Deng J, Wu Y, Yen R, Yegnasubramanian S, Rothbart S, Luo C, Wu L, Liu J, Baylin S, Kong X
Nature Communications 2025;16(1)
Nature Communications 2025;16(1)
DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis
Xu S, Yuan Z, Jiang C, Chen W, Li Q, Chen T
Advanced Science 2024;11(16)
Advanced Science 2024;11(16)
Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.
Fuller AM, DeVine A, Murazzi I, Mason NJ, Weber K, Eisinger-Mathason TSK
Cellular oncology (Dordrecht, Netherlands) 2022 Dec;45(6):1277-1295
Cellular oncology (Dordrecht, Netherlands) 2022 Dec;45(6):1277-1295
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
Xu S, Jiang C, Lin R, Wang X, Hu X, Chen W, Chen X, Chen T
Journal of Experimental & Clinical Cancer Research 2021;40(1)
Journal of Experimental & Clinical Cancer Research 2021;40(1)
JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.
Babu G, Chaudhuri P, Rajappa M, Biswas M, Sansar B, Rajegowda C, Radhakrishnan A, Advani J, Tewary B, Radhakrishnan P, Thiyagarajan S, Chatterjee A, Upadhayaya RS, Majumder PK
Cancer biology & therapy 2021 Jan 2;22(1):66-78
Cancer biology & therapy 2021 Jan 2;22(1):66-78
Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells
Xie Z, Dang Y, Wu H, He R, Ma J, Peng Z, Rong M, Li Z, Yang J, Jiang Y, Chen G, Yang L
Journal of Cancer 2020;11(10):2830-2844
Journal of Cancer 2020;11(10):2830-2844
No comments: Submit comment
No validations: Submit validation data